Pfizer cuts earnings outlook on lower Covid-19 drug sales

Italia Notizia Notizia

Pfizer cuts earnings outlook on lower Covid-19 drug sales
Italia Ultime Notizie,Italia Notizie

The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday. The sharp revision to expected sales of Paxlovid, an oral antiviral drug, and the Covid-19 vaccine Comirnaty sent Pfizer's stock tumbling.

The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treatIt now"anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion," Pfizer announced in a statement.

The sharp revision to expected sales of Paxlovid, an oral antiviral drug, and the Covid-19 vaccine Comirnaty sent Pfizer's stock tumbling.

 

Italia Ultime Notizie, Italia Notizie



Render Time: 2025-01-10 02:10:31